Table 6.
Pre-eclampsia and risk of any cancer in later life
| Study, country | Study design | Exposure | Race | Parity | Definition of exposure | No with pre-eclampsia/No of women | Mean follow-up (years) | Total cases cancer | Relative risk (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Minimum SBP, minimum DBP (mm Hg) | Minimum proteinuria g/24 h | |||||||||
| Irgens 2001,w15 Norway | RC | Pre-eclampsia 16-36 weeks; pre-eclampsia ≥37 weeks | White | P | —, 85 | — | 2649; 21 506/626 272 | 13 | 123*; 1973* | 0.36 (0.12 to 1.11); 0.90 (0.29 to 2.78) |
| Funai 2005, w17 Israel | RC | Pre-eclampsia | Mixed | Any | 140, 90 | † | 1070/37 061 | 30 | 658‡ | 1.26 (0.85 to 1.86) |
| Aagaard-Tillery 2006,w25 USA | RC | Pre-eclampsia | Mixed | Any | §, § | § | 15 859/65 692 | 7-59 | 3377¶ | 0.91 (0.84 to 0.99) |
| Total | 41 084/729 025 | 13.9** | 6131 | |||||||
SBP=systolic blood pressure, DBP=diastolic blood pressure; RC=retrospective cohort; P=primiparous. All papers adjusted for maternal age, year of birth, and hospital of delivery.
*Codes 140-239 from international classification of diseases, ninth revision and birth record data.
†Proteinuria (and oedema) must be present, no minimum value specified.
‡Israeli cancer registry.
§Codes 6424-6427 from international classification of diseases, ninth revision.
¶Utah cancer registry.
**Overall mean years of follow-up calculated without Aagaard-Tillery data because of presented range only.